SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotechnology Value Fund, L.P.
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: scaram(o)uche who wrote (973)10/2/1999 11:45:00 AM
From: Sidney StreetRead Replies (2) of 4974
 
I agree with Peter about shooting for 5x - 10x not 50-100; the AVM I mentioned earlier bumped a little yesterday, I think on the WSJ article about "sentinel node" techniques for avoiding stripping out all lymph nodes after dx of breast cancer. AVM's working on a more conservative approach, apparently both for initial staging and then treatment:

CAMBRIDGE, Mass., Aug. 4 /PRNewswire/ -- Advanced Magnetics, Inc. (Amex: AVM) today announced it has
received a grant from the National Cancer Institute of the National Institutes of Health totaling $98,706 for a
research project titled "Sentinel Lymph Node Staging with Magnetic Nanoparticles."

"Sentinel lymph node staging is a key diagnostic tool used in breast cancer staging and diagnosis," stated Jerome
Goldstein, Chairman and CEO of Advanced Magnetics. "Currently, patients who are having sentinel node staging
done receive a radioactive dye at the tumor site. They then undergo a surgical procedure to follow the path of the
dye to the sentinel node - the primary lymph node for tumor drainage - which is then removed and analyzed in a
laboratory. Our research, using Combidex(R) magnetic resonance imaging lymph node agent and Code 7228
second-generation lymph node agent, may non- invasively provide the same information as the current surgical
procedure." Mr. Goldstein continued: "We have been working with several clinicians in the field to evaluate the use
of our products to assist in sentinel node staging. We feel this is an exciting opportunity for our products to make a
difference in how patients are diagnosed and treated."
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News